Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited announced that all resolutions proposed at their Annual General Meeting (AGM) were approved. This includes the review and approval of the 2024 annual report, financial report, and profit distribution plan. Additionally, the reappointment of Grant Thornton Zhitong Certified Public Accountants LLP as the auditor for 2025 was confirmed. The AGM also approved the remuneration for directors and supervisors and proposed amendments to the Articles of Association. The successful passing of these resolutions signifies a stable operational outlook and continued strategic direction for the company, potentially reinforcing its position in the pharmaceutical market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in the People’s Republic of China, operating within the pharmaceutical industry. The company is primarily involved in the production and distribution of pharmaceutical products.
Average Trading Volume: 4,632,376
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.69B
Learn more about 0719 stock on TipRanks’ Stock Analysis page.